OTLK Stock Price
Outlook Therapeutics, Inc.
OTLK stock price is $0.47 (-16.60% on the day), giving Outlook Therapeutics, Inc. a market cap of $114.47M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
OTLK Stock Overview
- Price
- $0.47
- Previous close
- $0.56
- Open
- $0.56
- Market cap
- $114.47M
- P/E ratio
- -1.8
- 52-week range
- $0.16 - $2.54
- 1-year price target
- $5.03
- Exchange
- NSC
- MarketXLS Rank
- 23
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OTLK | $0.47 | -16.6% | 9.54M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Outlook Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW